1-8 of 8
David T. Weaver
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia

Xiangmeng Wang, Po Yee Mak, Hong Mu, Wenjing Tao, Arvind Rao, Ravikumar Visweswaran, Vivian Ruvolo, Jonathan A. Pachter, David T. Weaver, Michael Andreeff, Bing Xu, Bing Z. Carter
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2020) 19 (8): 1636–1648.
https://doi.org/10.1158/1535-7163.MCT-19-0841
Published: 04 August 2020
View article titled, Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia
Open the PDF for Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia in another window
Includes: Supplementary data
Journal Articles

Focal Adhesion Kinase as a Potential Target in AML and MDS

Bing Z. Carter, Po Yee Mak, Xiangmeng Wang, Hui Yang, Guillermo Garcia-Manero, Duncan H. Mak, Hong Mu, Vivian R. Ruvolo, Yihua Qiu, Kevin Coombes, Nianxiang Zhang, Brittany Ragon, David T. Weaver, Jonathan A. Pachter, Steven Kornblau, Michael Andreeff
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (6): 1133–1144.
https://doi.org/10.1158/1535-7163.MCT-16-0719
Published: 01 June 2017
View article titled, Focal Adhesion Kinase as a Potential Target in AML and MDS
Open the PDF for Focal Adhesion Kinase as a Potential Target in AML and MDS in another window
Includes: Supplementary data
Journal Articles

Abstract A191: FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy

Jennifer E. Ring, Yajuan Li, Irina M. Shapiro, Yan Wang, David T. Weaver, Jonathan A. Pachter
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): A191.
https://doi.org/10.1158/1535-7163.TARG-15-A191
Published: 01 December 2015
View article titled, Abstract A191: FAK/PYK2 inhibitors defactinib and VS-4718 enhance immune checkpoint inhibitor efficacy
Journal Articles

Abstract B197: Focal adhesion kinase inhibition enables efficacy of checkpoint immunotherapy in pancreatic cancer

Hong Jiang, Brett L. Knolhoff, Samarth Hedge, Yu Zhu, John Herndon, Irina M. Shapiro, David T. Weaver, Jonathan A. Pachter, David G. Denardo
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B197.
https://doi.org/10.1158/1535-7163.TARG-15-B197
Published: 01 December 2015
View article titled, Abstract B197: Focal adhesion kinase inhibition enables efficacy of checkpoint immunotherapy in pancreatic cancer
Journal Articles

Abstract A36: Combined inhibition of PI3K isoforms and mTOR kinase is critical for cancer stem cell inhibition by VS-5584

Vihren N. Kolev, Quentin G. Wright, David T. Weaver, Mahesh V. Padval, Jonathan A. Pachter, Qunli Xu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (7_Supplement): A36.
https://doi.org/10.1158/1538-8514.PI3K14-A36
Published: 06 July 2015
View article titled, Abstract A36: Combined inhibition of PI3K isoforms and mTOR kinase is critical for cancer stem cell inhibition by VS-5584
Journal Articles

Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells.

Christian M. Vidal, Vihren N. Kolev, Quentin G. Wright, Winnie F. Tam, David T. Weaver, Mahesh V. Padval, Qunli Xu, Jonathan A. Pachter
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C271.
https://doi.org/10.1158/1535-7163.TARG-13-C271
Published: 01 November 2013
View article titled, Abstract C271: FAK inhibitor defactinib (VS-6063) enhances the efficacy of paclitaxel and preferentially targets ovarian cancer stem cells.
Journal Articles

Abstract B52: Dual mTORC1/2 and PI3K inhibitor VS-5584 preferentially targets cancer stem cells.

Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal, Jennifer E. Ring, Irina M. Shapiro, David T. Weaver, Mahesh V. Pavdal, Jonathan A. Pachter, Qunli Xu
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B52.
https://doi.org/10.1158/1535-7163.TARG-13-B52
Published: 01 November 2013
View article titled, Abstract B52: Dual mTORC1/2 and PI3K inhibitor VS-5584 preferentially targets cancer stem cells.
Journal Articles

Abstract A31: Merlin loss as a biomarker for defactinib (VS-6063) sensitivity: High frequency in malignant mesothelioma tumors.

David T. Weaver, Irina Shapiro, Christian Vidal, Qunli Xu, Mahesh Padval, Jonathan Pachter, Daniel Paterson, Jullianne Barlow, William Richards, Sabina Signoretti, Raphael Bueno
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A31.
https://doi.org/10.1158/1535-7163.TARG-13-A31
Published: 01 November 2013
View article titled, Abstract A31: Merlin loss as a biomarker for defactinib (VS-6063) sensitivity: High frequency in malignant mesothelioma tumors.